
|Articles|March 1, 2001
- Pharmaceutical Executive-03-01-2001
- Volume 0
- Issue 0
Surrounded
Author(s)Wayne Koberstein
}Drug costs continue to rise at an alarming rate. Two major reasons for the increasing costs are introductions of new drugs and direct-to-consumer advertising campaigns that have been effective in marketing expensive name brand drugs.}
Advertisement
Articles in this issue
about 25 years ago
Research: New Horizonsabout 25 years ago
Earnings: Tough Times Aheadabout 25 years ago
Outbreak: Anthrax Alarmabout 25 years ago
Patents: China on the Genome Mapabout 25 years ago
Privacy, Pediatrics, and Policyabout 25 years ago
Lilly's International Familyabout 25 years ago
Update: Punishment and Reprieveabout 25 years ago
Shortage: Vaccine Worriesabout 25 years ago
Gateway to JapanNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AI has Redefined Healthcare Communication — and There’s No Opting Out
2
Novo Nordisk Signs Deal with Hims & Hers
3
Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals
4
How FDA's Removal of the Two-Trial Requirement Affects Development Programs
5




